INCIDENCE AND MANAGEMENT OF TREATMENT-RELATED SIDE EFFECTS FOR PATIENTS RECEIVING PLATINUM THERAPY IN AN OUTPATIENT ONCOLOGY CLINIC
Â Objective: Platinum agents (PAs) are the most commonly used chemotherapeutic agents, aiming to induce tumor cell death by cytotoxicity. This leads to have high potential for toxicity and adverse effects. The main objectives of this study were to describe the incidence of side effects caused by platinum therapy and to conclude the management of treatment-related side effects for patients receiving platinum therapy.
Methods: A descriptive, retrospective study was carried out over a period of 9 months. Laboratory reports of 100 cancer patients were recorded. All statistical analyses were performed using SPSS 17.0 and GraphPad Prism. A p<0.05 (95% confidence interval) was considered significantly throughout the study.
Results: Among 100 patients 55% were male and 45% were female. A total of 70% (n=70) patients who received platinum compounds as chemotherapy regimen, among them 97.14% (n=68) patients appears to have anemia. Among the occurrence of adverse drug reactions, the incidence of anemia was found to be significant (n=68, 97.14%). Statistically significant difference was found in the incidence of anemia between PAs and non- PAs treated group (p=0.0001).
Conclusion: Among PAs cisplatin-induced anemia and nephrotoxicity appears to be high in this study. There is a need to improve the management of anemia induced by PAs. Since anemia is preventable, this study emphasizes the need to improve the management of anemia induced by PAs.
BC Decker; 2003. p. 759-79.
2. Guminski AD, Harnett PR, deFazio A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 2002;3(5):312-8.
3. Florea AM, BÃ¼sselberg D. Cisplatin as an antitumor drug: Cellular mechanisms of activity, Drug resistance and induced side effects. Cancers (Basel) 2011;3(1):1351-71.
4. Oâ€™Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59 Suppl 4:19-27.
5. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8(1):10-6.
6. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51.
7. Lazo JS. Bleomycin. Cancer Chemother Biol Response Modif 1999;18:39-45.
8. Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, et al. Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011;8(4):332-8.
9. Swathi B, Bhavika D, Begum N. Adverse drug reaction profiles of commonly used platinum compounds in cancer chemotherapy. Int J Basic Clin Pharmacol 2015;4(2):284-9.
10. Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, Olivetto E, et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep 2013;29(4):1285-92.
11. Tjulandin SA, Bias P, ElsÃ¤sser R, Gertz B, Kohler E, Buchner A, et al. Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: A randomised controlled trial. Arch Drug Inf 2010;3(3):45-53.
12. Arunkumar PA, Viswanatha GL, Radheshyam N, Mukund H, Belliyappa MS. Science behind cisplatin-induced nephrotoxicity in humans: A clinical study. Asian Pac J Trop Biomed 2012;2(8):640-4.
13. Tenti E, Gardin IC, Frassineti L, Amador D, Minguzzi M. Increase of reports of suspected adverse drug reactions in oncology. Int J Pharm Pharm Sci 2014;6(9):95-6.
14. Antony A, Joel J, Shetty J, Umar NF. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Pharm Sci 2016;8(7):448-51.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.